| 证券代码 | ECYT.O |
| 证券名称 | Endocyte Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2011-02-04 |
| 首发价格(元) | 6 USD |
| 首发数量(股) | 12500000 |
| 首发募资额(元) | 75,000,000.00 USD |
| 首发主承销商 | Leerink Swann LLC,RBC Capital Markets, LLC |
| 货币单位 | USD |
| 公司名称 | Endocyte, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana, USA |
| 成立日期 | 2001 |
| 董事会主席 | John C. Aplin |
| 公司属地 | United States 美国 |
| 公司网址 | www.endocyte.com |
| 电话 | +1 (765) 463-7175 |
| 传真 | +1 (765) 463-9271 |
| 公司简介 | Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the personalized treatment of cancer. The company's drug conjugation technology targets therapeutics and companion imaging agents specifically to the site of diseased cells. Endocyte's lead program is a prostate specific membrane antigen (PSMA)-targeted radioligand therapy, 177Lu-PSMA-617, in phase 3 for metastatic castration-resistant prostate cancer (mCRPC). |